InDex Pharmaceuticals Holding AB (publ) announced the composition of the nomination committee for the 2024 Annual General Meeting. The nomination committee for the 2024 Annual General Meeting of the company consists of: Karl Tobieson, appointed by Linc; Ivo Staijen, appointed by HBM Healthcare Investments; Jan Särlvik, appointed by Fjärde AP-fonden; Björn Wasing, appointed by SEB-Stiftelsen and S-E-Bankens Utvecklingsstiftelse; Wenche Rolfsen, Chairman of the Board (convener).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.409 SEK | +1.24% | +2.56% | +56.25% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+56.25% | 19.86M | |
+30.38% | 684B | |
+29.82% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.27% | 240B | |
+9.00% | 208B | |
-7.61% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- INDEX Stock
- News InDex Pharmaceuticals Holding AB
- InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee